Authors: Masiello, David; Tulpule, Anil

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 10, July 2009 , pp. 1687-1698(12)

Publisher: Informa Healthcare

Abstract:

Background: Bendamustine is now approved in the US for the treatment of chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma, and is currently being explored in the treatment of several solid tumor types. Objective: The bi-functionality of bendamustine was used to provide a therapeutic understanding of both its benefit as well as adverse effects. Methods: Pertinent biochemistry and molecular biology pathways are reviewed with regards to bendamustine activity. In view of these pathways bendamustine was reviewed in human clinical trials. Results/conclusion: Bendamustine combines alkylating properties with purine analogue properties making it an effective drug in chronic lymphocytic leukemia where agents that affect these pathways have proven useful. There is limited evidence of cross-reactivity with this agent and other pure purine analogues and alkylators.

Keywords: alkylator; bendamustine; chemotherapy; CLL; leukemia; pharmacology

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14656560903032698

Publication date: 2009-07-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Masiello, David ;  Tulpule, Anil

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers